期刊文献+

克拉霉素对卡麦角林药物动力学的影响:健康对照和帕金森病例研究

下载PDF
导出
摘要 目的观察克拉霉素在健康对照和帕金森患者对卡麦角林药物动力学的影响。方法 10例健康受试者随机分为口服卡麦角林(1mg/d)6d,或口服克拉霉素(400mg/d)6d,7例帕金森患者接受稳定剂量的卡麦角林治疗,给予口服克拉霉素(400mg/d,6d)治疗前及治疗后测定卡麦角林血药浓度,停止应用克拉霉素1个月后再次检测。结果健康男性受试者卡麦角森的平均Cmax和AUC0~10h增加,平均血浆卡麦角林浓度应用克拉霉素者增加2.6倍,持续10h。在帕金森患者,全用克拉霉素后血浆卡麦角林浓度增加1.7倍。结论合用克拉霉素可增加健康和帕金森患者卡麦角林的药物浓度。
出处 《中国医药指南》 2012年第9期191-193,共3页 Guide of China Medicine
  • 相关文献

参考文献11

  • 1Goetz CG,Poewe W,Rascol O. Evidence-based medical review update:pharmacological and surgical treatments of Parkinson's disease:2001 to 2004[J].Movement Disorders,2005,(05):523-539.doi:10.1002/mds.20464.
  • 2Deleu D,Northway MG,Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease[J].Clinical Pharmacokinetics,2002,(04):261-309.doi:10.2165/00003088-200241040-00003.
  • 3Del Dotto P,Bonuccelli U. Clinical pharmacokinetics of cabergoline[J].Clinical Pharmacokinetics,2003,(07):633-645.doi:10.2165/00003088-200342070-00003.
  • 4Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4:an update focused on clarithromycin,azithromycin and dirithromycin[J].British Journal of Clinical Pharmacology,2000,(04):285-295.
  • 5Ausband SC,Goodman PE. An unusual case of clarithromycin associated ergotism[J].Journal of Emergency Medicine,2001,(04):411-413.doi:10.1016/S0736-4679(01)00379-1.
  • 6Christensen J,Dupont E,Ostergaard K. Cabergoline plasma concentration is increased during concomitant treatment with itraconazole[J].Movement Disorders,2002,(06):1360-1362.doi:10.1002/mds.10250.
  • 7Jokinen MJ,Ahonen J,Neuvonen PJ. Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine[J].Pharmacology and Toxicology,2001,(02):187-191.
  • 8Karyekar CS,Eddington ND,Briglia A. Renal interaction between itraconazole and cimetidine[J].Journal of Clinical Pharmacology,2004,(08):919-927.
  • 9孙斌.多巴胺受体激动剂治疗帕金森病[J].解放军保健医学杂志,2002,4(3):137-140. 被引量:4
  • 10王新德,孙相如,罗毅,王纪佐,蒋雨平,陈生弟.α-二氢麦角隐亭治疗帕金森病的临床多中心观察[J].中华老年医学杂志,2003,22(2):105-107. 被引量:3

二级参考文献4

  • 1Youdim, Moussa B. H. , Riederer, et al. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease[J]. Neurology, 2004, 63:S32 -35.
  • 2William J. Weiner. Initial Treatment of Parkinson Disease: Levodopa or Dopamine Agonists[ J ]. Arch Neurol, 2004, 61 : 1966 - 1969.
  • 3Hauser RA and Zesiewicz TA. Management of early Parkinson's Disease[J]. Medical Clinics of North America. 1999, 83(2):393 -414.
  • 4陈海波,曾湘豫,张文记,秦斌,郑剑晖,李淑华,王新德.帕金森病运动功能评分量表及一致性和敏感性检验[J].卒中与神经疾病,2001,8(1):1-4. 被引量:37

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部